VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Wednesday, highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations.
“We are encouraged by the strong interest from potential partners in our BiTAC platform and bispecific ADC programs,” said Dr. Maria Schultz, CEO of VERAXA Biotech. “Our strategy to prioritize BiTAC development while monetizing non-core assets positions us to advance our pipeline efficiently and create long-term value for shareholders.” The company said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s BiTAC platform is designed to generate bispecific T-cell engagers with optimized properties for treating solid tumors. The pipeline update follows the company’s participation at the BIO International Convention, where management held partnering meetings with several pharmaceutical companies.
The company’s focus on T-cell engagers and ADCs comes as the biopharmaceutical industry increasingly turns to these modalities for cancer treatment. T-cell engagers harness the immune system by redirecting T cells to cancer cells, while ADCs deliver potent cytotoxic drugs directly to tumors. VERAXA’s bispecific ADC programs combine the targeting capabilities of bispecific antibodies with ADC technology, potentially improving efficacy and reducing side effects.
VERAXA’s non-BiTAC assets include two programs that the company is seeking to monetize through licensing or partnership deals. The proceeds from such transactions would be used to finance the development of the BiTAC portfolio, including VXA-102. The company expects to provide further updates on partnering activities and pipeline milestones in the coming months.
VERAXA Biotech AG trades on the Nasdaq under the ticker VRXA. More information is available in the company’s newsroom at http://ibn.fm/VRXA.
